Global Alzheimer's Disease Blood Diagnostic Market Growth (Status and Outlook) 2024-2030

Global Alzheimer's Disease Blood Diagnostic Market Growth (Status and Outlook) 2024-2030

Alzheimer's Disease (AD) blood diagnostic refers to a clinical test or series of tests that analyze specific biomarkers present in the blood to identify and diagnose Alzheimer's Disease. These diagnostics aim to detect the presence of pathological changes associated with AD, such as amyloid plaques, tau tangles, neurodegeneration, and other related abnormalities, using minimally invasive blood samples.

Alzheimer's Disease blood diagnostics represent a promising advancement in the field of neurodegenerative disease detection. By leveraging specific biomarkers and advanced analytical techniques, these tests offer a non-invasive, accessible, and potentially cost-effective means of diagnosing and monitoring Alzheimer's Disease, ultimately improving patient outcomes through earlier and more accurate diagnosis.

The global Alzheimer's Disease Blood Diagnostic market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.

LPI (LP Information)' newest research report, the “Alzheimer's Disease Blood Diagnostic Industry Forecast” looks at past sales and reviews total world Alzheimer's Disease Blood Diagnostic sales in 2022, providing a comprehensive analysis by region and market sector of projected Alzheimer's Disease Blood Diagnostic sales for 2023 through 2029. With Alzheimer's Disease Blood Diagnostic sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Alzheimer's Disease Blood Diagnostic industry.

This Insight Report provides a comprehensive analysis of the global Alzheimer's Disease Blood Diagnostic landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Alzheimer's Disease Blood Diagnostic portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Alzheimer's Disease Blood Diagnostic market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Alzheimer's Disease Blood Diagnostic and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Alzheimer's Disease Blood Diagnostic.

United States market for Alzheimer's Disease Blood Diagnostic is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Alzheimer's Disease Blood Diagnostic is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Alzheimer's Disease Blood Diagnostic is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Alzheimer's Disease Blood Diagnostic players cover Quanterix, C2N Diagnostics, Sysmex, Quest Diagnostics, Roche Diagnostics, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Alzheimer's Disease Blood Diagnostic market by product type, application, key players and key regions and countries.

Segmentation by Type:
Amyloid Beta (Aβ)
Tau Proteins
Others

Segmentation by Application:
Early Diagnosis
Clinical Research

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Segmentation by Type:
Amyloid Beta (Aβ)
Tau Proteins
Others

Segmentation by Application:
Early Diagnosis
Clinical Research

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Quanterix
C2N Diagnostics
Sysmex
Quest Diagnostics
Roche Diagnostics
Eli Lilly and Company
Fujirebio
Amoneta Diagnostics
MagQu
Vazyme
KingMed Diagnostics
Anqun Bioengineering

Please note: The report will take approximately 2 business days to prepare and deliver.